Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aquestive, Assertio, BMS, Ignyte, JW, Kissei, Obseva, Obsidian, Peak, Res Nova, Soligenix and Therapeutic Solutions.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied, Astrazeneca, Atai, Avrobio, Can-Fite, Cardiol, Gristone, Imaginab, Inotrem, Oblato, Quadriga, Seelos and Ultimovacs.
Inotrem SA obtained an unexpectedly robust efficacy signal from a curtailed phase II trial of nangibotide, an inhibitor of triggering receptor expressed on myeloid cells 1, in patients with severe COVID-19.
Sinocelltech Group Ltd. has reported positive interim data for two COVID-19 vaccine candidates, SCTV-01C and SCTV-01E, from phase III trials in the United Arab Emirates.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Acumen, Astrazeneca, Daiichi, JJP, Leo, Merck & Co., Novaliq, Novavax, Sensorion, Vanda, Vaxxinity.
Researchers from Emory University have discovered a novel broadly neutralizing SARS-CoV-2 antibody, 002-S21F2, being developed as a potential anti-coronavirus therapeutic.
RSS
